For instance, the addition of ganitumab, a monoclonal antibody targeting IGF-1R, to carboplatin/paclitaxel chemotherapy in patients with primary epithelial ovarian cancer did not improve progression-free survival in a phase II multicenter controlled trial (65), despite the promising results of IGF-1R inhibition in various preclinical studies (25, 32, 64). The gene discussed is IGF1R; the disease is ovarian carcinoma.